We examined the influence of HRT use on breast cancer (BCa) risk among Slovenian postmenopausal women (784 cases and 709 controls aged 50-69 years). HRT use was inversely associated with BCa risk. The effect was most pronounced with estrogen use only but longer duration of HRT use did not result in evident improvement. Obesity, smoking 10 or more cigarettes/day and any first degree relative with breast/ovarian cancer were positively associated with BCa risk. Our analysis revealed some differences from the previously published literature, which might reflect underlying demographic changes.
COBISS.SI-ID: 28234457
We investigated the independent and the combined effects of two commonly occurring polymorphisms in MTHFR 677C>T (rs1801133) and MTHFR 1298A>C (rs1801131) as well as their interaction with hormone replacement therapy (HRT) use on their potential contribution to breast cancer risk. We studied 530 breast cancer cases and 270 controls of the same age and ethnicity participating in a case-control study of postmenopausal women. No significant association was observed between both, the individual and the combined MTHFR genotypes and the risk of postmenopausal breast cancer.
COBISS.SI-ID: 1027195
We evaluated the contribution of X chromosome mosaicism in phenotypically normal women with sporadic POF. During 1999-2008, 114 patients with POF and 64 age-matched controls were karyotyped. Thirteen patients (11.4%) had “true” X chromosome mosaicism and twelve had (10.5%) “low-level” X-mosaicism. In the control group the incidence of cells with an abnormal number of X chromosomes was 1-3%. The results have practical implications for genetic counseling and fertility treatment.
COBISS.SI-ID: 28233945
To our knowledge this is the first report of FMR1 premutation, sex chromosome mosaicism and blood lymphocyte microchimerism as the cause of premature ovarian failure. We discussed the phenotypic features and presented successful pregnancy outcomes after in vitro fertilization-embryo transfer with donated oocytes.
COBISS.SI-ID: 27118041
This was the first Slovene study evaluating the exposure to antihypertensive therapy in pregnancy during a five-year period. We presented the cases with possible effects of treatment with specific angiotensin II receptor blocker (ARBs) on the fetus. We have concluded that women should be informed that ARB-antihypertensive therapy must be replaced/stopped before planning their pregnancy or at least immediately after confirmation of pregnancy. Fetal morphology scan and monitoring of the amniotic fluid volume should be obligatory, if ARBs are prescribed accidentally.
COBISS.SI-ID: 25691353